GSK plc GLAXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.95B | 11.29B | 10.28B | 11.46B | 11.52B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.95B | 11.29B | 10.28B | 11.46B | 11.52B |
| Cost of Revenue | 3.01B | 2.78B | 2.52B | 3.48B | 3.02B |
| Gross Profit | 8.94B | 8.51B | 7.75B | 7.98B | 8.51B |
| SG&A Expenses | 2.92B | 2.94B | 2.81B | 3.55B | 2.92B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -22.86M | -273.85M | -828.58M | -577.21M | -190.13M |
| Total Operating Expenses | 8.47B | 7.80B | 6.55B | 9.29B | 7.87B |
| Operating Income | 3.48B | 3.49B | 3.73B | 2.17B | 3.66B |
| Income Before Tax | 2.60B | 475.22M | 2.89B | 1.26B | 3.31B |
| Income Tax Expenses | 312.00M | -267.14M | 410.92M | 296.58M | 420.70M |
| Earnings from Continuing Operations | 2.29B | 742.36M | 2.48B | 966.88M | 2.89B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -215.17M | -158.41M | -137.42M | -121.03M | -176.64M |
| Net Income | 2.08B | 583.95M | 2.34B | 845.86M | 2.71B |
| EBIT | 3.48B | 3.49B | 3.73B | 2.17B | 3.66B |
| EBITDA | 4.47B | 3.79B | 4.35B | 3.58B | 4.50B |
| EPS Basic | 0.52 | 0.15 | 0.58 | 0.21 | 0.67 |
| Normalized Basic EPS | 0.45 | 0.48 | 0.51 | 0.28 | 0.49 |
| EPS Diluted | 0.51 | 0.14 | 0.57 | 0.21 | 0.66 |
| Normalized Diluted EPS | 0.44 | 0.47 | 0.51 | 0.27 | 0.49 |
| Average Basic Shares Outstanding | 4.01B | 4.01B | 4.02B | 4.02B | 4.03B |
| Average Diluted Shares Outstanding | 4.07B | 4.06B | 4.07B | 4.09B | 4.10B |
| Dividend Per Share | 0.23 | 0.23 | 0.23 | 0.24 | 0.22 |
| Payout Ratio | 44.20% | 167.13% | 37.02% | 101.57% | 32.29% |